Why patients lose weight after bariatric operations;Warum Patienten nach bariatrischen Operationen Gewicht abnehmen

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 135, Issue 1, 2010, Pages 28-33

  Bueter, M ^a   Seyfried, F ^b   Germer, C T ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Appetite; Gastric bypass; Gastrointestinal hormones; Obesity; Satiety

Indexed keywords

GASTROINTESTINAL HORMONE;

APPETITE; ARCUATE NUCLEUS; ARTICLE; CALORIC INTAKE; FEEDING BEHAVIOR; HUMAN; INTESTINE ABSORPTION; METHODOLOGY; MORBID OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOPHYSIOLOGY; STOMACH BYPASS; WEIGHT REDUCTION;

APPETITE; ARCUATE NUCLEUS; ENERGY INTAKE; FEEDING BEHAVIOR; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; HUMANS; INTESTINAL ABSORPTION; OBESITY, MORBID; SATIETY RESPONSE; WEIGHT LOSS;

EID: 77149180427     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0029-1224697     Document Type: Article

References (65)

1. Hedley A A., Ogden C L., Johnson C L. et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 19992002. JAMA 2004 291 2847-2850
2. Visscher T L., Seidell J C. The public health impact of obesity. Annu Rev Public Health 2001 22 355-375
3. Kaplan L M. Pharmacological therapies for obesity. Gastroenterol Clin North Am 2005 34 91-104
4. Adams T D., Gress R E., Smith S C. et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007 357 753-761
5. Sjostrom L, Narbro K, Sjostrom C D. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007 357 741-752
6. Buchwald H, Estok R, Fahrbach K et al. Weight and type2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009 122 248-256
7. Busch P, Wolter S, Rawnaq T et al. Operative Technik und deren Outcome in der metabolischen Chirurgie: Konventioneller und Banded Gastric Bypass. Zentralbl Chir 2009 134 32-37
8. Brolin R E., LaMarca L B., Kenler H A. et al. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg 2002 6 195-203
9. Pournaras D J., le Roux C W. After bariatric surgery what vitamins should be measured and what supplements should be given? Clin Endocrinol (Oxf) 2009 71 322-325
10. Crenn P, Morin M C., Joly F et al. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. Gut 2004 53 1279-1286
11. le Roux C W., Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007 246 780-785
12. Wren A M., Seal L J., Cohen M A. et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001 86 5992-5992
13. Balasubramaniam A, Mullins D E., Lin S et al. NeuropeptideY (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. JMed Chem 2006 49 2661-2665
14. Schwartz M W., Woods S C., Porte Jr D et al. Central nervous system control of food intake. Nature 2000 404 661-671
15. Cone R D., Cowley M A., Butler A A. et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001 25 Suppl5 S63-S67
16. Flier J S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004 116 337-350
17. Grill H J., Smith G P. Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 1988 254 (6Pt2) R853-R856
18. Murakami N, Hayashida T, Kuroiwa T et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 2002 174 283-288
19. Wren A M., Small C J., Abbott C R. et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001 50 2540-2547
20. Neary N M., Small C J., Wren A M. et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004 89 2832-2836
21. Cummings D E., Purnell J Q., Frayo R S. et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001 50 1714-1719
22. le Roux C W., Neary N M., Halsey T J. et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005 90 4521-4524
23. Druce M R., Wren A M., Park A J. et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005 29 1130-1136
24. Cummings D E., Weigle D S., Frayo R S. et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002 346 1623-1630
25. le Roux C W., Patterson M, Vincent R P. et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005 90 1068-1071
26. Holst J J. On the physiology of GIP and GLP-1. Horm Metab Res 2004 36 747-754
27. Abbott C R., Monteiro M, Small C J. et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005 1044 127-131
28. Edwards C M., Stanley S A., Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001 281 E155-E161
29. Gutzwiller J P., Goke B, Drewe J et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999 44 81-86
30. Feinle C, Chapman I M., Wishart J et al. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 2002 23 1491-1495
31. Edwards C M., Todd J F., Mahmoudi M et al. Glucagon-like peptide1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999 48 86-93
32. Villanueva-Penacarrillo M L., Marquez L, Gonzalez N et al. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 2001 33 73-77
33. Guerci B, Martin C S. Exenatide: its position in the treatment of type2 diabetes. Ann Endocrinol (Paris) 2008 69 201-209
34. Soltani N, Kumar M, Glinka Y et al. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin- induced diabetes. Gene Ther 2007 14 981-988
35. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980 285 417-418
36. Adrian T E., Ferri G L., Bacarese-Hamilton A J. et al. Human distribution and release of a putative new gut hormone, peptideYY. Gastroenterology 1985 89 1070-1077
37. Adrian T E., Savage A P., Sagor G R. et al. Effect of peptideYY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985 89 494-499
38. le Roux C W., Batterham R L., Aylwin S J. et al. Attenuated peptideYY release in obese subjects is associated with reduced satiety. Endocrinology 2006 147 3-8
39. Chelikani P K., Haver A C., Reidelberger R D. Intravenous infusion of peptideYY (3-36) potently inhibits food intake in rats. Endocrinology 2005 146 879-888
40. Degen L, Oesch S, Casanova M et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005 129 1430-1436
41. Batterham R L., Cowley M A., Small C J. et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002 418 650-654
42. Batterham R L., Cohen M A., Ellis S M. et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003 349 941-948
43. White N E., Dhillo W S., Liu Y L. et al. Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice. Diabetes Obes Metab 2008 10 167-170
44. Adrian T E., Savage A P., Bacarese-Hamilton A J. et al. PeptideYY abnormalities in gastrointestinal diseases. Gastroenterology 1986 90 379-384
45. Di F V., Zamboni M, Dioli A et al. Delayed postprandial gastric emptying and impaired gallbladder contraction together with elevated cholecystokinin and peptideYY serum levels sustain satiety and inhibit hunger in healthy elderly persons. J Gerontol A Biol Sci Med Sci 2005 60 1581-1585
46. Creutzfeldt W, Ebert R, Willms B et al. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 1978 14 15-24 (Pubitemid 8260739)
47. Baggio L L., Drucker D J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007 132 2131-2157
48. Ding W G., Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 1997 46 615-621
49. Gibbs J, Young R C., Smith G P. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973 84 488-495
50. Liddle R A., Goldfine I D., Rosen M S. et al. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985 75 1144-1152
51. Moran T H. Cholecystokinin and satiety: current perspectives. Nutrition 2000 16 858-865
52. Batterham R L., le Roux C W., Cohen M A. et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003 88 3989-3992
53. le Roux C W., Aylwin S J., Batterham R L. et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006 243 108-114
54. Dixon A F., Dixon J B., OBrien P E. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 2005 90 813-819
55. Mason E E. The mechanisms of surgical treatment of type2 diabetes. Obes Surg 2005 15 459-461
56. Patriti A, Facchiano E, Sanna A et al. The enteroinsular axis and the recovery from type2 diabetes after bariatric surgery. Obes Surg 2004 14 840-848
57. Rubino F, Gagner M, Gentileschi P et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004 240 236-242
58. Neary N M., Small C J., Druce M R. et al. PeptideYY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005 146 5120-5127
59. Day J W., Ottaway N, Patterson J T. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009 5 749-757
60. Pocai A, Carrington P E., Adams J R. et al. GLP-1/GCGR dual agonism reverses obesity in mice. Diabetes 2009 58 2258-2266
61. Holdstock C, Engstrom B E., Ohrvall M et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003 88 3177-3183
62. Huttl T P., Obeidat F W., Parhofer K G. et al. Operative Techniken und deren Outcome in der metabolischen Chirurgie: Sleeve-Gastrektomie. Zentralbl Chir 2009 134 24-31
63. Karamanakos S N., Vagenas K, Kalfarentzos F et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008 247 401-407
64. Kellum J M., Kuemmerle J F., ODorisio T M. et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990 211 763-770
65. Ashrafian H, le Roux C W. Metabolic surgery and gut hormones A review of bariatric entero-humoral modulation. Physiol Behav 2009 97 620-631